Re: Additional Reports of Exempt Distribution

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Toinv

Rank: President [?]

Points: 4393 [?]

Votes: 35 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Additional Reports of Exempt Distribution

in response to

Re: Additional Reports of Exempt Distribution

Nextblockbuster

posted on Jul 24, 2023 05:11PM

What would happen if just 1 trial, for example, mcrpc was FDA approved for NDA and ready to hit the market?

Would this not almost immediately lead to the potential for revenue generation? And zen3694 has been in trials for years on mcrpc.